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a b s t r a c t
We set out to characterize the mechanical effects of myeloperoxidase (MPO) in isolated left-ventricular human
cardiomyocytes. Oxidative myoﬁlament protein modiﬁcations (sulfhydryl (SH)-group oxidation and carbonyla-
tion) induced by the peroxidase and chlorinating activities of MPO were additionally identiﬁed. The speciﬁcity
of the MPO-evoked functional alterations was tested with an MPO inhibitor (MPO-I) and the antioxidant amino
acid Met. The combined application of MPO and its substrate, hydrogen peroxide (H2O2), largely reduced the
active force (Factive), increased the passive force (Fpassive), and decreased the Ca2þ sensitivity of force production
(pCa50) in permeabilized cardiomyocytes. H2O2 alone had signiﬁcantly smaller effects on Factive and Fpassive and
did not alter pCa50. The MPO-I blocked both the peroxidase and the chlorinating activities, whereas Met
selectively inhibited the chlorinating activity of MPO. All of the MPO-induced functional effects could be
prevented by the MPO-I and Met. Both H2O2 alone and MPO þ H2O2 reduced the SH content of actin and
increased the carbonylation of actin and myosin-binding protein C to the same extent. Neither the SH oxidation
nor the carbonylation of the giant sarcomeric protein titin was affected by these treatments. MPO activation
induces a cardiomyocyte dysfunction by affecting Ca2þ-regulated active and Ca2þ-independent passive force
production and myoﬁlament Ca2þ sensitivity, independent of protein SH oxidation and carbonylation. The
MPO-induced deleterious functional alterations can be prevented by theMPO-I andMet. Inhibition of MPOmay
be a promising therapeutic target to limit myocardial contractile dysfunction during inﬂammation.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Oxidative stress-related myoﬁlament protein alterations have been
shown to play key roles in the impaired cardiomyocyte contractility in
response to myocardial inﬂammation, ischemia–reperfusion injury,
and left-ventricular (LV) remodeling after a myocardial infarction (MI)
[1,2]. In particular, reactive oxygen species (ROS) oxidize cellular com-
ponents [3], leading to cardiomyocyte contractile dysfunction, myo-
cyte apoptosis, or cardiac hypertrophy [4,5].
Myeloperoxidase (MPO; EC 1.11.2.2) is a member of the heme
peroxidase superfamily, synthesized by neutrophils, monocytes, and
macrophages, stored in their azurophilic granules, and released in
substantial amounts upon leukocyte activation [6]. MPO has beneﬁcial
effects on the innate host defense mechanisms [7]. Considerable
evidence has emerged to suggest that ROS formation by MPO pro-
motes various deleterious actions in the cardiovascular (CV) system
and contributes to the development of CV diseases [6]. Individuals
with a total or subtotal MPO deﬁciency (a defect with a frequency of
E1 in every 2000 to 4000 Caucasians) are protected from CV diseases
[6]. An elevated level of circulating MPO is a prognostic marker of
mortality and predicts the risks of subsequent major adverse cardiac
events in patients with acute coronary syndrome (ACS) [8], particu-
larly in association with a low LV ejection fraction [9]. MPO also
contributes to adverse LV remodeling after an MI [10]. MPO exerts
adverse effects on the vasculature, oxidizes low-density lipoprotein
[11], impairs high-density lipoprotein function [12], and reduces the
bioavailability of nitric oxide (NO) [13]. MPO can therefore serve as a
valuable biomarker of inﬂammation in coronary artery disease and
ACS [14]. The serum level of MPO correlates positively with the
severity of LV dysfunction and seems to be an essential factor in the
development and exacerbation of heart failure (HF) [15,16]. Interest-
ingly, the MPO concentration was earlier found not to differ in
ischemic and nonischemic cardiomyopathy, suggesting that MPO has
an independent pathogenic role in LV dysfunction [17].
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MPO is known to generate numerous reactive oxidants and
diffusible radical species via its peroxidase and chlorinating activities,
which are capable of promoting an array of reversible and irrever-
sible posttranslational protein modiﬁcations [18,19]. The relative
concentrations of chloride and the reducing substrate determine
whether MPO uses its substrate hydrogen peroxide (H2O2) for
peroxidation or chlorination. MPO ampliﬁes the oxidative potential
of H2O2 [20–22], which may originate from a number of sources
in vivo, including leukocyte NADPH oxidases, xanthine oxidase, and
uncoupled NO synthase [23,24]. The perfusion of isolated rat hearts
with H2O2 led to disulﬁde cross-bridge formation in actin and
tropomyosin (Tm) [25]. In one of our previous studies, the sulfhydryl
(SH) oxidation of actin and myosin light chain-1 (MLC-1) was
suggested as the mechanism in H2O2-evoked depressed cardiomyo-
cyte contractility [26].
MPO is unique in its ability to create hypochlorous acid (HOCl; a
potent antimicrobial agent) through its chlorinating activity [22].
Interestingly, the cardiac tissue is highly susceptible to oxidation even
by physiological concentrations of HOCl [27]. Importantly, HOCl is
much more effective than H2O2 in oxidizing proteins in the myocar-
dium [27], it causes SH oxidation [28] and carbonylation in myoﬁla-
ment proteins [29], it disturbs Ca2þ homeostasis and Ca2þ handling
[30], it increases the intracellular Ca2þ concentration in isolated rat
[31] and rabbit [32] ventricular cardiomyocytes, and it induces
cardiomyocyte death in rats [33]. It is also very important to consider
how far H2O2 or HOCl can diffuse on the cellular scale and whether
these substances are capable of penetrating cell membranes. H2O2 is
stable [34] and membrane permeative [35], but the in vivo concen-
tration of H2O2 highly depends on its generation and consumption
rates [36,37]. HOCl appears to be more toxic and reactive and can also
penetrate through cell membranes, but has a much shorter life span.
An in vitro study revealed that HOCl production by neutrophils can be
as high as 450 mM/h, which was shown to be less in an in vivo model
[38]. MPO generates HOCl in micromolar concentrations [39], but in
inﬂamed tissue it is estimated to be as high as 5 mM [40].
The antioxidant amino acid methionine (Met) acts as a sca-
venger of HOCl and has been shown to prevent HOCl-induced
morphological changes and contractile dysfunction in murine
myocytes [41]. Moreover, the fact that MPO-derived chlorinating
compounds can serve as speciﬁc biomarkers for disease progres-
sion has attracted considerable interest in the development of
therapeutically useful MPO inhibitors (MPO-I’s) [42].
Although the role of MPO-derived oxidants in the pathogenesis of
myocardial ischemia and HF is relatively well established, only limited
data are available as concerns the exact cellular and subcellular
mechanisms through which MPO could directly affect the contractility
of myocardial cells, especially at the level of the myoﬁbrillar proteins.
In this study, therefore, we set out (1) to characterize the functional
effects of MPO and its substrate H2O2 on single, permeabilized human
cardiomyocytes; (2) to identify the biochemical alterations induced by
the peroxidase and chlorinating activities of MPO; (3) to investigate
the speciﬁcity of the MPO-induced contractile changes by using the
MPO-I 4-aminobenzhydrazide and the antioxidant amino acid Met;
and (4) to explore the MPO-related reversible and irreversible
oxidative myoﬁlament protein modiﬁcations in the human LV myo-
cardium.
Materials and methods
Human myocardial samples
LV myocardial tissue was obtained from the hearts of four
general organ-donor patients (41- and 46-year-old women and
53- and 57-year-old men). All of these patients were free of any
cardiac abnormalities and had not received any medication except
for plasma volume expanders, dobutamine, and furosemide. The
cause of death included cerebral contusion, cerebral hemorrhage,
and subarachnoidal hemorrhage. All biopsies were transported in
cardioplegic solution (pH 7.4; in mM: NaCl 110, KCl 16, MgCl2 1.6,
CaCl2 1.2, NaHCO3 5) and were frozen in liquid nitrogen and stored
at 80 1C at the laboratory. The experiments on human tissues
complied in full with the Helsinki Declaration of the World
Medical Association and were approved by the Hungarian Ministry
of Health (No. 323-8/2005-1018EKU) and by the Institutional
Ethics Committee at the University of Debrecen, Hungary.
Force measurements in permeabilized cardiomyocyte preparations
Force measurements were performed as described previously
[43]. In brief, frozen tissue samples were ﬁrst defrosted and
mechanically disrupted in cell isolation solution (Iso) (in mM:
KCl 100, ethylene glycol tetraacetic acid 2, MgCl2 1, Na2ATP 4,
imidazole 10; pH 7.0) containing phenylmethylsulfonyl ﬂuoride
(PMSF, 0.5 mM, Sigma–Aldrich, St. Louis, MO, USA), leupeptin (40
μM, Sigma–Aldrich), and E-64 (10 μM, Sigma–Aldrich) protease
inhibitors. The mechanically isolated cells were skinned by incu-
bation in Iso supplemented with 0.5% (v/v) Triton X-100 (Sigma–
Aldrich) for 5 min. Triton X-100 was removed by washing at least
three times in Iso (1 ml in each washing step) and the skinned
myocytes were kept in Iso on ice until the measurements. A
skinned single cardiomyocyte was mounted between two thin
needles, which were attached to a force transducer element
(SensoNor, Horten, Norway) and an electromagnetic motor (Aur-
ora Scientiﬁc, Aurora, ON, Canada) through the use of silicone
adhesive (DAP, Baltimore, MD, USA) for determination of the
mechanical parameters. The measurements were performed at
15 1C on the stage of a light microscope. The average sarcomere
length was adjusted to 2.3 μm.
The compositions of the relaxing and activating solutions used
during force measurements were calculated as described previously
[43]. Both solutions were supplemented with protease inhibitors:
leupeptin (40 μM) and E-64 (10 μM). The pCa’s, i.e., the  log10[Ca2þ]
values of the relaxing and activating solutions (pH 7.2), were 9.0 and
4.75, respectively. Solutions with intermediate free Ca2þ levels were
obtained by mixing activating and relaxing solutions [44]. Isometric
force production was measured after the preparation had been
transferred from the relaxing solution to a set of Ca2þ-containing
solutions. When a steady force level had been reached, the length of
the myocyte was reduced by 20% within 2 ms, and the myocyte was
then quickly restretched (release–restretch maneuver). As a result, the
force ﬁrst dropped from the peak isometric level to 0 (difference ¼
total peak isometric force, Ftotal) and then started to redevelop. About
6 s after the onset of force redevelopment, the cardiomyocyte was
returned to the relaxing solution, in which the length of the myocyte
was again reduced by 20% for 8 s to determine the Ca2þ-independent
passive force component (Fpassive). The Ca2þ-activated isometric force
(Factive) was calculated by subtracting Fpassive from Ftotal. Factive at
submaximal levels of activation was normalized to that at maximal
activation (pCa 4.75). Thereafter, the normalized force values were
plotted against the Ca2þ concentration of the activating solutions to
create a sigmoidal curve, to determine the Ca2þ sensitivity of force
production (pCa50). Maximal active force was also tested at the end of
the experiments at pCa 4.75. Experiments that yielded a value below
80% of the initial value were discarded.
To determine the mechanical consequences of myoﬁlament pro-
tein oxidation, cardiomyocytes were exposed to Iso supplemented
with H2O2 (30 μM, Sigma–Aldrich) for 15 min, MPO þ H2O2 (8 U/L,
Abcam, Cambridge, UK) for 15 min, MPO þ H2O2 þ MPO-I 4-amino-
benzhydrazide (50 mM, Cayman Chemicals, Ann Arbor, MI, USA) for 15
min, or MPO þ H2O2 þ Met (10 mM, Sigma–Aldrich) for 15 min at
15 1C. The reversibility of MPO þ H2O2-evoked effects was examined
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by the application of the reducing agent dithiothreitol (DTT; Sigma–
Aldrich, 10 mM, 30 min) to MPO þ H2O2-treated cardiomyocytes.
Force–pCa relationships and pCa50 values were determined before and
after the application of these agents. The effects of the applied agents
on Factive and Fpassive were expressed relative to their control
(untreated, before application of the agent at pCa 4.75 and pCa 9.0,
respectively). Changes in Factive and Fpassive upon application of the
agents were compared with the force values measured after incuba-
tion of the cardiomyocytes in Iso for 15 min (time control).
Measurements of MPO activities
MPO chlorination and peroxidation assay kits (Cayman Chemicals)
were used. The chlorination activity assay utilizes a nonﬂuorescent
substrate (APF; 2-(6-(4-aminophenoxy)-3-oxo-3H-xanthen-9-yl)ben-
zoic acid), which is cleaved by theMPO-generated hypochlorite (OCl)
to produce highly ﬂuorescent ﬂuorescein. The peroxidase activity
assay uses a nonﬂuorescent substrate (ADHP; 10-acetyl-3,7-dihydrox-
yphenoxazine), which is converted by MPO to the ﬂuorescent
resoruﬁn. Fluorescence was detected with a NovoStar microplate
reader (BMG Labtech, Ortenberg, Germany) at λex 485 nm and λem
520 nm in the chlorination assay and at λex 544 nm and λem 590 nm
in the peroxidase assay. The reaction solution contained the nonﬂuor-
escent substrate (APF (18 mM) or ADHP (45 mM)), assay buffer
(phosphate-buffered saline (PBS), pH 7.4), and H2O2 (30 mM) or
MPO þ H2O2 (38 U/L) or MPO þ H2O2 þ MPO-I (50 mM) or MPO
þ H2O2 þ Met (10 mM). Activities were measured for 5 min at 24-s
intervals. Fluorescence intensities were ﬁtted by linear regression
analysis (before saturation) and the slope of this relation was used
to calculate MPO activities. Values were corrected for the background
(the activity determined in the absence of MPO).
Biochemical assays for the identiﬁcation of oxidative protein
modiﬁcations
Ellman’s reaction
Overall myoﬁlament SH-group content was determined by Ell-
man’s reaction. Skinned cardiomyocytes were treated with Iso (time
control) or with Iso supplemented with H2O2 and MPO as described
for the mechanical experiments. Washing steps followed the treat-
ments and the cardiomyocytes were then incubated for 15 min in
Ellman’s reagent (5,50-dithiobis(2-nitrobenzoic acid); Sigma–Aldrich),
which reacts with myoﬁlament SH groups and produces the yellow 2‐
nitro‐5‐thiobenzoic acid (NTB). The absorbance of NTB was measured
with a NovoStar microplate reader at 412 nm. N-acetyl-L-cysteine
(NAC; Sigma–Aldrich) was used to calibrate the NTB absorbance in
relation to the amount of SH groups. A known concentration of NAC
was reacted with Ellman’s reagent and the absorbance at 412 nm,
ﬁtted with a single exponential, served as the calibration curve. The
SH contents in 1-mg lyophilized myocardial samples were calculated
from the measured absorbance, the tissue weight, and the calibration
curve. Measurements were performed in triplicate.
Protein SH oxidation
Cardiomyocytes were isolated from LV myocardial samples (25 mg
wet weight) as for the functional measurements and were treated in
Iso (150 ml) containing H2O2 (30 mM) or MPO þ H2O2 (38 U/L) for 15
min. Cardiomyocytes exposed to dithiodipyridine (DTDP; 2.5 mM, for
2 min) were used as positive controls. Protein SH groups were labeled
with EZ-Link Iodoacetyl-LC-Biotin (Thermo Scientiﬁc, Rockford, IL,
USA, for 60 min in the dark, at room temperature) in a reaction buffer
(containing EDTA 5 mM, Tris–HCl 50 mM, pH 8.3, and 0.1 mg/ml
biotin) according to the manufacturer’s instructions (biotin was
dissolved in dimethyl formamide (Sigma–Aldrich) and diluted in
reaction buffer to 0.1 mg/ml). After the biotinylation process, the
myocytes were solubilized in sample buffer (containing 8 M urea, 2 M
thiourea, 3% (w/v) sodium dodecyl sulfate (SDS), 75 mM DTT, 50mM
Tris-HCl, pH 6.8, 10% (v/v) glycerol, bromophenol blue), 10 mM E-64,
and 40 mM leupeptin (1 h, under continuous agitation). Protein
concentration was determined in the supernatant with a dot–blot-
based method, using bovine serum albumin (BSA; Sigma–Aldrich) as a
standard. Protein concentration was adjusted to 1 mg/ml. Polyacryla-
mide gels (2, 4, (strengthened with 0.5% agarose), 10, and 15%) and 4–
15% gradient gels (Bio-Rad, Hercules, CA, USA) were used to separate
myoﬁlament proteins before blotting to nitrocellulose membranes.
Proteins were quantitated with the ﬂuorescent Sypro ruby protein blot
stain (Invitrogen, Eugene, OR, USA). Membranes were blocked with
10% (w/v) milk powder diluted in PBS containing 0.1% (v/v) Tween 20
(PBST). Biotin-labeled SH groups were probed with peroxidase-
conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA,
USA) at a ﬁnal concentration of 5 ng/ml for 30 min. Signal intensities
of biotin-labeled SH groups were visualized by an enhanced chemi-
luminescence (ECL) method and normalized for those assessed with
the Sypro ruby protein blot stain.
Protein disulﬁde cross-bridge formation
Similar to the experiments by Canton et al. [45], human LV
myocardial samples were solubilized in reducing (1 Laemmli
sample buffer (Sigma–Aldrich) containing 2% SDS, 10% glycerol, 5%
β-mercaptoethanol (β-ME), 0.0625 M Tris–HCl, pH 6.8) and non-
reducing (same buffer without β-ME) sample buffer after H2O2 or
MPO þ H2O2 treatment. SDS–PAGE was performed using 10%
polyacrylamide gels, and thereafter proteins were transferred onto
nitrocellulose membranes. After the nonspeciﬁc binding sites were
blocked, the membranes were probed with monoclonal anti-
tropomyosin (1:10,000, clone CH1) or monoclonal anti-actin
(1:1000, clone HHF35, Dako Cytomation, Glostrup, Denmark)
antibodies.
Detection of protein carbonyl groups
Cardiomyocytes from LV myocardial tissue (15 mg wet weight)
were incubated with H2O2 and MPO, as described above. Cardiomyo-
cytes treated with the Fenton reagent (50 mM FeSO4, 6 mM ascorbic
acid, and 1.5 mM H2O2 for 7 min) were used as positive controls for
protein carbonylation. Cardiomyocytes were washed after treatment
and solubilized in sample buffer containing 8 M urea, 3% (w/v) SDS, 50
mM Tris–HCl (pH 6.8), 10 mM E-64, and 40 mM leupeptin for 1 h by
vortexing. The samples were then centrifuged (16,000g for 5 min) and
the supernatants were used for carbonyl group derivatization based
on the formation of 2,4-dinitrophenylhydrazone from 2,4-dinitrophe-
nylhydrazine (OxyBlot Protein Oxidation Detection Kit, Millipore,
Billerica, MA, USA). After derivatization (15 min), samples were
centrifuged (1000g for 1 min) and the pellet was dissolved in a buffer
containing 8 M urea, 2 M thiourea, 3% (w/v) SDS, 75 mM DTT, 50 mM
Tris-base (pH 14), 10% (v/v) glycerol, and bromophenol blue (30 min,
shaking). Derivatized samples were centrifuged (16,000g for 5 min)
and the protein concentrations of the supernatants were determined
with a dot–blot-based method, using a BSA standard. The protein
concentration of the samples was adjusted to 1mg/ml. Polyacrylamide
gel electrophoresis with 2, 4, (strengthened with 0.5% agarose), 10, and
15% gels and 4–15% gradient gels was carried out to separate
myoﬁlament proteins. Proteins were transferred onto nitrocellulose
membranes and visualized with the Sypro ruby protein blot stain. The
membranes were then blocked with 2% (w/v) BSA in PBST for 30 min
and probed with primary and secondary antibodies (rabbit anti-DNP
antibody 1:150, 1 h, and goat anti-rabbit IgG 1:300, 1 h) diluted in 1%
(w/v) BSA–PBST according to the manufacturer’s instructions. Protein
bands were visualized by the ECL method. Signal intensities deter-
mined by OxyBlot assay were normalized for those assessed with the
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Sypro ruby protein blot stain. The extent of carbonylation was
expressed as carbonylation index (CI ¼ 1 in the time control samples).
Data analysis and statistics
Cardiomyocyte force generationwasmeasured with a custom-built
system (utilizing the DAQ platform produced by National Instruments,
Austin, TX, USA) and recorded by a custom-built LabVIEW (National
Instruments) module. Results were evaluated in Excel (Micro-
soft, 2007) and GraphPad Prism 5.0 (GraphPad Software, San Diego,
CA, USA).
Ca2þ–force relations were ﬁtted to a modiﬁed Hill equation,
Ftotal ¼ Fmax Ca2þ
h inHill
= pCa50
nHillþ Ca2þ
h inHill 
þFpassive;
where Fmax is the maximal force, Fpassive is the passive force, Ftotal
¼ Fmax þ Fpassive, [Ca2þ] is the calculated Ca2þ concentration,
nHill is a constant, and pCa50 corresponds to the [Ca2þ] at which
Ftotal  Fpassive ¼ Fmax/2.
The results of the measurements for each cardiomyocyte were
ﬁtted individually. Factive and Fpassive values were normalized to the
cardiomyocyte cross-sectional area and expressed in kN/m2. The
number of experiments in each group varied between 5 and 12
from three or four different hearts.
Western immunoblot assays were performed in triplicate. Inten-
sities of protein bands were quantiﬁed by determining the area under
the intensity curves by a Gaussian ﬁt using ImageJ (National Institutes
of Health, Bethesda, MD, USA) and Magic Plot (Saint Petersburg,
Russia) software. Graphs were created in GraphPad Prism 5.0 sof-
tware.
Differences between groups were calculated by analysis of variance
(followed by Bonferroni’s post hoc test) or multilevel mixed-effects
linear regression analysis, to appropriately address nonindependence
between multiple observations from the same heart. The null hypoth-
esis for all group means being equal was tested, followed by pairwise
between-groups comparisons based on the variance–covariance mat-
rix of the ﬁxed effects. Comparisons of normalized pCa–force rela-
tionships determined upon subsequent applications of the agents
were performed with paired and unpaired t tests. Group descriptions
were based on the mean and SEM values. Statistical signiﬁcance was
accepted at p o 0.05.
Results
MPO þ H2O2 impairs the contractile function in human
cardiomyocytes
When permeabilized human LV cardiomyocytes (Fig. 1A) were
treated with Iso containing MPO (8 U/L) and H2O2 (30 μM), a
signiﬁcant decrease in the maximal Ca2þ-dependent (pCa 4.75) Factive
and a marked increase in the Ca2þ-independent (pCa 9.0) Fpassive were
observed (to 57.7 7 4.1 and 179.6 7 14.6% of untreated, respectively,
n ¼ 12) (Fig. 1B). The decrease in the isometric force at various free
Ca2þ concentrations was signiﬁcantly larger in response to MPO þ
H2O2 application than that in the presence of H2O2 alone (Fig. 1C).
Incubation of cardiomyocytes with Iso (time control) resulted in only a
minor change in Factive (to 89.0 7 1.6%). The MPO-induced increase in
Fpassive was signiﬁcantly higher than that evoked by H2O2 alone (79.6
7 14.6% vs 23.9 7 7.4%, p o 0.001; Fig. 1D). When the peak
contractile forces measured at intermediate Ca2þ concentrations were
normalized to their respective maximum, a signiﬁcant rightward shift
in the pCa–force relationship, i.e., a decrease in the Ca2þ sensitivity of
force production (pCa50) was observed after MPO þ H2O2 treatment
(from 5.83 7 0.02 to 5.66 7 0.02, p o 0.001; Fig. 1E). In contrast, the
application of H2O2 alone did not alter pCa50 (5.85 7 0.05 vs 5.82 7
0.03, p ¼ 0.55; Fig. 1F). The differences in the baseline cardiomyocyte
maximal Factive, Fpassive, and pCa50 were 5.4, 5.5, and 0.9%, respectively.
The light microscopic morphology did not reveal visible alterations in
the cross-striation pattern of the cardiomyocytes upon MPO þ H2O2
or H2O2 treatment (data not shown).
Met inhibits the chlorinating but not the peroxidase activity of MPO
To identify the biochemical mechanism underlying the functional
effects of MPO, we measured its chlorinating and peroxidase activities
in the presence of the MPO-I and Met (Fig. 2A and B). The MPO-I
diminished both the chlorinating and the peroxidase activities of MPO
(to 0.3 7 0.2 and 10.4 7 6.0%, respectively, p o 0.001, n ¼ 4).
However, Met selectively inhibited the chlorinating activity of MPO (to
2.3 7 1.3%, p o 0.001, n ¼ 4), without signiﬁcantly affecting its
peroxidase activity (78.4 7 8.6%, n ¼ 4).
MPO-I and Met completely prevent, whereas DTT partially reverses,
the MPO-induced cardiomyocyte dysfunction
To assess whether the MPO-I or Met is also able to prevent the
deleterious mechanical effects of MPO, cardiomyocytes were incu-
bated with MPO þ H2O2 in the presence of the MPO-I (50 μM) or Met
(10 mM). Both the MPO-I and Met prevented the MPO-induced
decrease in Factive (to 80.0 7 5.3 and 80.1 7 3.6% of untreated,
respectively, p o 0.001; Fig. 3A) and the increase in Fpassive (to 147.7
7 6.1 and 139.9 7 8.7% of untreated, respectively, p o 0.05, n ¼ 5 or
6; Fig. 3B). Factive and Fpassive measured after the application of the
MPO-I or Met to MPO þ H2O2 were similar to those determined after
H2O2 treatment. Moreover, the MPO-I (Fig. 3C) or Met (Fig. 3D)
completely abolished the rightward shift in the pCa–force relation-
ships observed upon combined MPO þ H2O2 treatment (5.88 7 0.07
vs 5.66 7 0.02, p o 0.05, and 5.81 7 0.04 vs 5.66 7 0.02,
respectively, p o 0.001 vs MPO þ H2O2, n ¼ 5 or 6). The changes
in pCa50 measured after H2O2, MPO þ H2O2, MPO-I, and Met
treatments are illustrated in Fig. 3E. The reversibility of the MPO þ
H2O2-evoked functional alterations was tested by application of the
reducing agent DTT (10 mM) to the cardiomyocytes (n ¼ 6). The
increase in Fpassive after MPO þ H2O2 (ΔFpassive 89.3 7 27.3%
compared to untreated) was almost completely reversed after DTT
treatment (ΔFpassive 9.7 7 10.4% compared to untreated, p o 0.05).
DTT, however, did not signiﬁcantly affect Factive (to 57.7 7 4.1 and to
43.8 7 5.1% of untreated after MPO þ H2O2 and DTT administration,
respectively, p ¼ 0.13; ﬁgure not shown).
Effects of MPO þ H2O2 on the SH oxidation and carbonylation of
myoﬁlament proteins
Attempts were made to identify the changes in the oxidative status
of myoﬁlament proteins contributing to the MPO-induced cardiomyo-
cyte dysfunction in parallel with the functional measurements.
Relative SH contents were determined in human LV skinned cardio-
myocytes. The baseline SH content of myoﬁlament proteins in the
donor heart samples varied between 98.0 7 4.6 and 104.1 7 3.9% (p
¼ 0.35). Ellman’s reaction revealed a small but signiﬁcant decrease in
the overall amount of SH groups in response to H2O2 (to 90.4 7 1.5%,
p o 0.05, n ¼ 3) or MPO þ H2O2 treatment (to 86.7 7 4.0%, p o
0.01, n ¼ 3; Fig. 4A). An SH-group biotinylation assay was applied to
identify individual myoﬁbrillar proteins affected by MPO-mediated SH
oxidation. Samples treated with the oxidative agent DTDP were used
as positive controls. H2O2 and MPO þ H2O2 lowered the SH content of
actin to similar extents (to 75.9 7 7.1%, p o 0.01, n ¼ 4, and 84.2 7
4.4%, p o 0.05 vs time control, respectively, n ¼ 9; Fig. 4B). In
contrast, the SH contents of myosin-binding protein C (MyBP-C,
Fig. 4C) and the more compliant (N2BA) and stiffer (N2B) isoforms
of the giant sarcomeric protein titin were not affected by these
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treatments (Figs. 4D–4F). On immunoblots a Tm- and an actin-
containing complex was observed at approximately 90-kDa molecular
mass under nonreducing conditions (in a buffer not containing β-ME);
however, no increase in its intensity or that of Tm and actin could be
detected after H2O2 and MPO þ H2O2 treatments (Fig. 5).
Protein carbonylation assays revealed a modest but signiﬁcant
increase in the carbonylation of actin upon H2O2 treatment (CI ¼ 1.1
7 0.046, p o 0.05 vs the time control, n ¼ 5), which was not further
affected by the addition of MPO (CI ¼ 1.1 7 0.052, p ¼ 0.9 vs H2O2, n
¼ 11; Fig. 6A). Similar to actin, a slight, but signiﬁcant increase in the
carbonyl content of MyBP-C was observed both after H2O2 (CI ¼ 1.5
7 0.2, p o 0.05 vs the time control, n ¼ 2) and after MPO þ H2O2
application (CI ¼ 1.4 7 0.2, p o 0.05 vs the time control, n ¼ 4;
Fig. 6B). The extent of carbonyl group formation in the N2BA and N2B
titin isoforms remained unaltered after H2O2 or MPO þ H2O2
treatment (CI ¼ 0.9 7 0.2 and CI ¼ 1.0 7 0.2 for N2BA; CI ¼ 1.0
7 0.1 and CI ¼ 0.9 7 0.1 for N2B, respectively; Figs. 6C–6E).
Discussion
This is the ﬁrst reported investigation of the direct effects of MPO
on the contractile function of single, isolated human myocardial cells.
The in vitro model experiments revealed that (1) MPO impairs Ca2þ-
dependent isometric force generation, increases the Ca2þ-indepen-
dent Fpassive, and decreases the Ca2þ sensitivity of force production;
(2) theMPO-induced functional changes can be prevented by anMPO-
I and the antioxidant Met; (3) the levels of SH oxidation in actin and of
carbonylation in actin and MyBP-C are increased by the application of
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MPO þ H2O2 or H2O2 alone; and (4) the MPO-evoked functional
effects are probably mediated by the chlorinating activity of MPO.
Myocardial inﬂammation and ischemia–reperfusion injury are
characterized by enhanced oxidative stress and contractile dysfunc-
tion [46]. The application of MPO þ H2O2 to human cardiomyocytes
appreciably reduced the Ca2þ-activated Factive and markedly
decreased pCa50. In contrast, H2O2 (30 μM) alone induced a smaller
decrease in Factive. Consistent with our ﬁndings, a lower concentra-
tion of H2O2 (10 μM) did not result in a decrease in the maximal
Ca2þ-activated force in skinned rat heart preparations [47,48]. This
suggests that the action of H2O2 on contractile force generation is
concentration-dependent. Lower concentrations have no measurable
effects, whereas higher concentrations affect the cardiomyocyte
contractility. The deleterious effect on Factive can be explained by
the MPO-mediated H2O2-derived production of HOCl. In a previous
study, HOCl treatment alone (10 and 50 μM for 1 min) evoked a
signiﬁcant decrease in the maximum Ca2þ-activated force [47],
similar to the result of MPO þ H2O2 treatment in the present study.
Interestingly, neither the H2O2- nor the MPO-induced functional
changes were related to any deterioration in the cross-striation
pattern of the cardiomyocytes under the light microscope. It is
important to note, however, that electron microscopy has revealed
a myoﬁlament lattice disruption after HOCl treatment [47].
The subtle increase after H2O2 application and the marked eleva-
tion in the Ca2þ-independent Fpassive upon MPO þ H2O2 treatment in
the present study are consistent with the observations that H2O2 at
low (o10 mM) concentration did not alter Fpassive, whereas HOCl (10
and 50 μM) induced a signiﬁcant rise in Fpassive of skinned rat
trabeculae [48]. It is well established that the giant sarcomeric protein
titin plays a key role in the development of Fpassive in permeabilized
cardiomyocytes by acting as a molecular spring in the sarcomere [49].
The cardiomyocyte Fpassive can be modulated by the titin isoform
switch (between the short and stiff N2B and the longer and more
compliant N2BA isoform [50]) and by several posttranslational mod-
iﬁcations, including phosphorylation [51], SH oxidation [52], and
potentially carbonylation. One elegant study demonstrated that the
oxidative stress-induced formation of disulﬁde bridges within the titin
molecule (N2B unique sequence, N2B-Us) reduced the contour length
of the N2B-Us, leading to stiffening of the whole titin molecule [52]. In
the present study, neither SH oxidation nor carbonylation of the N2B
and N2BA titin isoforms was affected by MPO or H2O2 treatment. This
may be explained by the distinct sensitivities of the titin N2B isoform,
actin, and MyBP-C to oxidative changes based on the differences in
their ultrastructures and SH-group contents. Our results indicate that
modiﬁcations other than titin SH oxidation or carbonylation might be
responsible for the marked elevation in Fpassive after MPO treatment in
human cardiomyocytes.
The signiﬁcant decrease observed in pCa50 after MPO þ H2O2 in
this study is in marked contrast with the previous ﬁnding of an
increase in pCa50 in skinned rat trabeculae in response to HOCl
treatment [48]. This apparently conﬂicting result might be explained
by (1) the different concentration of HOCl produced by the MPO under
our experimental conditions, (2) a difference in susceptibility of the
myoﬁlaments to HOCl between the two species, and (3) the difference
in the experimental setting, permeabilized, single cardiomyocytes
presenting a negligible diffusion obstacle in comparison with trabe-
culae. Further, the pronounced MPO-induced decrease in pCa50
suggests that different myoﬁlament protein modiﬁcations occur and
contribute to pCa50 in the course of MPO and H2O2 treatments. Under
these experimental conditions H2O2 more probably induced a struc-
tural, rather than a regulatory, alteration in the contractile apparatus
because pCa50 was not affected. The deleterious effect on the maximal
Factive and the modest increase in Fpassive upon H2O2 administration
imply that the H2O2-induced contractile alterations could be explained
by a reduction in the number of force-generating cross-bridges due to
the diminished longitudinal transmission of force along the sarco-
meres. These ﬁndings are consistent with the observations of Mac-
Farlane and Miller [53], who exposed chemically skinned rat cardiac
muscles to the superoxide anion (from which H2O2 formed endogen-
ously through spontaneous or superoxide dismutase-catalyzed dis-
mutation). They also found a dose-dependent reduction in the
maximal Factive without any alteration in the pCa50 and concluded
that some aspect of the cross-bridge behavior is particularly vulner-
able to superoxide [53].
A substantial amount of data indicates that the inhibition of MPO
may well be useful in CV pathologies characterized by elevated MPO
levels (myocardial inﬂammation, ischemia–reperfusion injury, and
acute MI). Thus, despite the fact that MPO-I’s may have adverse effects
on the function of MPO in the innate host-defense mechanisms,
potential therapeutic interventions through which to inhibit MPO have
aroused considerable interest [42]. In the present study, both theMPO-I
4-aminobenzhydrazide (50 mM) and the antioxidant amino acid
Met (10 mM) were equally able to prevent all of the MPO-evoked
deleterious contractile effects in skinned human cardiomyocytes, the
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latter potentially by scavenging the HOCl generated by MPO. MPO
activity assays suggested that the Met-inhibited chlorinating activity is
responsible for the MPO-evoked functional changes. HOCl reacts most
rapidly with the sulfur-containing residues (Met and Cys) [54]. It is
likely, therefore, that the high concentration of Met used in this study
diminished the HOCl-evoked oxidative capacity. The oxidation of Met
residues results in the generation of Met-sulfoxide (MetSO), a process
that may be reversed by MetSO reductase [55]. Met is therefore consi-
dered to play a protective role against the deleterious effects of protein
oxidation [28]. Interestingly, the incomplete reversion and oxidation of
physiologically relevant Met residues have been shown to contribute to
the impaired function of proteins [56], including actin [57]. It is
important to note that other HOCl-scavenging substances than Met
(e.g., glutathione, taurine, and L-ascorbic acid) were also tested recently
in HOCl-scavenging assays [58]. Given the rapid reaction rates of HOCl
with biological materials, however, much higher doses of L-ascorbic
acid and thiols were required to effectively protect against the direct
oxidative damage induced by HOCl. This suggests that inhibiting the
generation of HOCl may be a better choice than scavenging HOCl after
its generation, for amelioration of HOCl-induced biological damage.
The distinct effect of the reducing agent DTT on Factive and Fpassive
after MPO þ H2O2 treatment found in this study might be explained
by different modiﬁcations on the structural conformation or functional
activity of the contractile and regulatory myoﬁlament proteins. The
precise nature of the redox-dependent functional changes upon H2O2
and MPO þ H2O2 treatment is complex and determined also by the
type and site of the induced posttranslational modiﬁcations on
individual proteins within the sarcomere [59]. SH residues of Cys
0
50
100
150
*
*
SH
/m
g 
m
yo
cy
te
+ + +
+ +
+
Iso
H2O2
MPO
0
50
100
150
200
Iso
H2O2
MPO
DTDP
+ + + +
+ +
+
+
SH
 c
on
te
nt
 in
 N
2B
A
is
of
or
m
 o
f t
iti
n 
(%
)
0
50
100
150
200
Iso
H2O2
MPO
DTDP
+ + + +
+ +
+
+
SH
 c
on
te
nt
 in
 N
2B
is
of
or
m
 o
f t
iti
n 
(%
)
N2BA
N2B
T2
N2B
T2
N2BA
Total protein
SH content
+ + + +
+ +
+
+
Iso
H2O2
MPO
DTDP
SH content
Total protein
0
50
100
150
*
*
Iso
H2O2
MPO
DTDP
+ + + +
+ +
+
+
SH
 c
on
te
nt
 in
 a
ct
in
 (%
)
0
50
100
150
Iso
H2O2
MPO
DTDP
+ + + +
+ +
+
+
SH
 c
on
te
nt
 in
 M
yB
P-
C
 (%
)
SH content
Total protein
Fig. 4. MPO and H2O2 similarly alter SH group oxidation in myoﬁlament proteins. (A) SH-group oxidation in a cardiomyocyte suspension treated in Iso supplemented with
H2O2 and MPO (Ellman’s reaction). (B–E) Representative examples of SH-content determination in (B) actin, (C) myosin-binding protein C (MyBP-C), and (D, E) N2BA and (D,
F) N2B titin isoforms after H2O2 or MPO þ H2O2 treatment using a protein biotinylation assay. T2 indicates the titin degradation product. Samples exposed to
dithiodipyridine (DTDP; 2.5 mM, for 2 min) were used as positive controls. Total protein amount was determined with the Sypro ruby protein blot stain. Values are expressed
relative to the SH-group content determined in Iso (time control). Data are expressed as the mean 7 SEM, np o 0.05 vs Iso.
J. Kalász et al. / Free Radical Biology and Medicine 84 (2015) 116–127 123
can undergo both reversible and irreversible modiﬁcations. The
reaction between the Cys thiolate anion and H2O2 results in formation
of intra- or intermolecular disulﬁde bonds, which are reversible, but
further oxidation can generate sulﬁnic or sulfonic acid, which are
considered irreversible alterations [60]. The HOCl-induced protein
carbonylation is thought to be irreversible, whereas methionine
oxidation can be reversed by MetSO-reductase [28] or can lead to
an irreversible product (methionine-sulfone) [55].
The extent of overall SH oxidation observed after MPO treatment
in this study was comparable to that in heart tissue slices exposed to
high-dose HOCl [27]. There is biochemical evidence that oxidative
modiﬁcations modulate the architecture of the myoﬁlament protein
actin [61] and myosin [62]. In vitro exposure of permeabilized human
LV cardiomyocytes to the oxidative agent DTDP resulted in a decrease
in maximal Ca2þ-activated force production with a parallel reduction
in the SH content of actin and MLC-1 [26]. Consistent with this, in the
present study H2O2 decreased the SH content of actin. However,
despite the marked reduction in Factive, no additional decrease in this
parameter was detected after MPO þ H2O2 application, suggesting
that SH oxidation may not be the main contributor to the MPO-
evoked decrease in Factive under these experimental conditions. More-
over, formation of an actin- and a Tm-containing protein complex
observed in this study is also unlikely to be responsible for the
contractile changes in the cardiomyocytes after H2O2 and MPO þ
H2O2 administration. The possible functional consequences of the
formed protein complexes require further examinations.
In a mouse model of experimental MI, we recently identiﬁed the
increased carbonylation of actin and myosin heavy chain (MHC) in
the infarcted area [2]. Similar to MPO, in vitro Fenton-based
myoﬁlament carbonylation decreased pCa50, irrespective of the
phosphorylation status of the myoﬁlaments. Moreover, pCa50 corre-
lated strongly with the myoﬁlament carbonylation levels. In accord
with this, a marked (threefold) increase in carbonyl group formation
in actin was observed after 1 mM but not after 0.1 mM H2O2
treatment [25]. The application of H2O2 to cardiomyocytes at a
concentration higher than 0.1 mM was hindered by its inhibitory
effect on the activity of MPO [42]. H2O2 at 30 μM lowered Factive in
parallel with a slight, but signiﬁcant, increase in the carbonylation of
actin and MyBP-C. Similar to SH oxidation, carbonylation of these
myoﬁlament proteins was not further affected by the addition of
MPO, despite its noteworthy effects on cardiomyocyte active and
passive force production. This implies that the physiological effects
of MPO-catalyzed oxidative processes are independent of SH-group
oxidation or carbonylation of human myocardial proteins.
Oxidative modiﬁcations in the myocardium primarily have
been considered to result in reduced force generation, as also
demonstrated in the present study. However, recent evidence
suggests a more complex picture. Reactive oxygen and nitrogen
species can activate protective mechanisms and signaling path-
ways (redox regulation) [60] or even increase cardiac performance
[63]. Mild oxidative stress-induced S-nitrosylation at speciﬁc Cys
residues was shown to be cardioprotective [64]. Subtle increases in
ROS production may even enhance cardiac contractility under
physiological conditions [65]. Indeed, certain oxidative myoﬁla-
ment modiﬁcations can lead to positive functional consequences;
for example, nitroxyl (HNO), a reactive nitrogen species related to
nitric oxide, induces formation of actin–Tm heterodimers, which
correlates with the increase in Ca2þ sensitivity and dimeric forms
of MHC and MLC-1, which are associated with increased force
generation [63]. HNO was also shown to increase maximum
tension and Ca2þ sensitivity of trabecular sarcomere functioning
in situ [66]. These results strongly suggest that the beneﬁcial or
deleterious functional outcome is likely to be dictated by the
strength and the nature of the oxidizing agent and the redox
milieu of the myoﬁlament compartment.
Because isolation of cardiomyocytes and assessment of myoﬁ-
lament properties were performed on LV biopsies of unused donor
hearts, possible changes in the phosphorylation and oxidative
status of the myoﬁlament proteins occurring before or during
tissue sampling may have interfered with the results of this study.
In addition, activation of the β-adrenergic signaling and various
oxidative pathways might also inﬂuence the baseline mechanical
and biochemical characteristics of the cardiomyocytes. We have
checked the baseline functional parameters of the cells in the
study and found no major differences in the cardiomyocyte
mechanical properties. Moreover, the baseline myoﬁlament SH
contents were also similar in the LV samples used for the
cardiomyocyte isolation. These observations are in line with those
found in our previous study, in which the reducing agent DTT did
not affect Factive or pCa50 of cardiomyocytes derived from human
donor hearts [26].
In this study LV heart samples were frozen and their functional
and biochemical properties were evaluated upon thawing. To
validate the use of defrosted biopsy samples, in one of our
previous studies [67] force recordings of cardiomyocytes isolated
from a biopsy sample immediately after procurement were com-
pared to those of cardiomyocytes isolated from a defrosted biopsy
of the same patient. These force recordings yielded identical
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results. In addition, the extent of tissue heterogeneity was also
addressed in previous studies using explanted hearts [68,69] or
surgically procured biopsies [70]. In these studies the variability of
force measurements of cardiomyocytes isolated from different
portions of the heart was always less than 5%.
It is also important to note that several additional MPO-
sensitive processes, such as protein halogenation [71], protein
nitration [72], Met oxidation, sulfonic acid generation (Cys) [73], or
protein degradation [28], might be responsible for the observed
functional alterations. Further studies are clearly required to
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elucidate the relative contributions of these processes to the
overall pump function during human cardiac pathologies asso-
ciated with elevated MPO levels.
Conclusion
MPO-derived oxidants contribute to myocardial contractile
dysfunction by decreasing the cardiomyocyte force production
and the myoﬁlament Ca2þ sensitivity and increasing Fpassive in
human cardiomyocytes. These effects could be prevented by MPO
inhibition and the antioxidant Met. The associated functional and
biochemical alterations may provide a pharmacological tool for
the prevention and/or reversion of MPO-induced contractile pro-
tein alterations, which could have therapeutic implications in
cardiac pathologies characterized by elevated MPO levels.
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